BMS 193885
目录号 : GC14881
Competitive NPY Y1 receptor antagonist
Cas No.:679839-66-8
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
BMS-193885 is a potent and selective neuropeptide Y1 receptor antagonist with IC50 of 5.9nM.
Neuropeptide Y receptor 1 is G-protein coupled receptors and implicated in the modulation of food intake and energy homeostasis. Neuropeptide Y1 is expressed in many tissues including the hippocampus, hypothalamus, amygdala and the cortex of the brain as well as in peripheral tissues heart, kidney, skeletal muscle. The localization and expression suggests their involvement in the regulation of food intake and body weight.
In cellular culture, BMS-193885 displayed functional antagonism of Neuropeptide Y1 in a
forskolin-stimulated c-AMP production assay using CHO cells expressing the human Y(1) receptor 1.
In vivo, administration of BMS-193885 at a dosage of 10mg/kg leads to 1h neuropeptide Y-induced food intake in rat and the spontaneous overnight food consumpetion 2 . Chronic administration of BMS-193885 (10 mg/kg) i.p. for 44 days significantly reduced food intake and the rate of body weight gain as compared to their control without developing tolerance or affecting water intake 2.
References:
1. Poindexter GS, Bruce MA, LeBoulluec KL, et al. Dihydropyridine neuropeptide Y Y(1) receptor antagonists. Bioorganic & medicinal chemistry letters. 2002;12(3):379-382.
2. Antal-Zimanyi I, Bruce MA, Leboulluec KL, et al. Pharmacological characterization and appetite suppressive properties of BMS-193885, a novel and selective neuropeptide Y(1) receptor antagonist. European journal of pharmacology. 2008;590(1-3):224-232.
| Cas No. | 679839-66-8 | SDF | |
| 化学名 | (S)-2-hydroxypropanoic acid compound with (Z)-N-(3-(3,5-bis(methoxycarbonyl)-2,6-dimethyl-1,4-dihydropyridin-4-yl)phenyl)-N'-(3-(4-(3-methoxyphenyl)piperidin-1-yl)propyl)carbamimidic acid (1:1) | ||
| Canonical SMILES | CC(N1)=C(C(OC)=O)C(C(C(OC)=O)=C1C)C2=CC(N/C(O)=N/CCCN3CCC(C4=CC(OC)=CC=C4)CC3)=CC=C2.C[C@@](O)([H])C(O)=O | ||
| 分子式 | C33H42N4O6.C3H6O3 | 分子量 | 680.79 |
| 溶解度 | <68.08mg/ml in DMSO; <13.62mg/ml in Water | 储存条件 | Desiccate at RT |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 1.4689 mL | 7.3444 mL | 14.6888 mL |
| 5 mM | 0.2938 mL | 1.4689 mL | 2.9378 mL |
| 10 mM | 0.1469 mL | 0.7344 mL | 1.4689 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Quality Control & SDS
- View current batch:
- Purity: >99.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet